CTLA4 exon 1 and promoter polymorphisms in patients with multiple sclerosis
G Yousefipour1, N Erfani, M Momtahan
1Department of Neurology, Shiraz University of Medical Sciences, Shiraz, Iran.
Objective:
The polymorphisms of exon 1 (+49 A/G) and promoter regions (-1722 T/C, -1661 A/G and -318 C/T)of cytotoxic T lymphocyte antigen 4 (CTLA4) and also haplotypes constructed from mentioned loci were investigated amongst 153 Iranian patients with definite multiple sclerosis (MS) and 190 healthy controls.
Methods:
The polymorphisms were genotyped by PCR-restriction fragment length polymorphisms and PCR-amplification refractory mutation system. The 4-locus haplotypes were estimated by Arlequin software (University of Berne, Berne, Switzerland).
Results:
Preliminary results showed significant increase of +49 G allele and -1661 AG genotype, as well as TGCA haplotype among patients than controls (P < 0.036, P = 0.009 and P < 0.010, respectively). The distribution of -1722 T/C, -1661 A/G, -318 C/T and +49 A/G (TACA) haplotype, from the contrary, was observed to be significantly increased among controls (P < 0.001).
Conclusions:
After Bonferroni correction, the results provide preliminary evidence that CTLA4 genetic variation at -1661 locus may render Iranian individuals to be more susceptible to MS, whereas harboring TACA haplotype might be protective.
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Multiple Sclerosis l: Introduction
Non-LTR Retrotransposons
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu


